Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omarigliptin add-on to glimepiride and metformin in type 2 diabetes mellitus
2012-002612-10Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Omarigliptin add-on arm with Placebo add-on arm (2 arms). Primary endpoint: Change from baseline in glycated hemoglobin. Started Feb 2013; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002612-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002612-10.